Preclinical Evaluation Of Neutralizing Antibodies Elicited by HIV-1 Immunogens
$320,240Z01FY2008AINIH
National Institute Of Allergy And Infectious Diseases
Investigators
Linked publications & trials
Paper 19264769Paper 19004960Paper 18833294Paper 18155743Paper 18052607Paper 17599382Paper 17360741Paper 17113201Paper 16690178Paper 16616287Paper 16460776Paper 16415019Paper 16194587Paper 16051804Paper 16051803Paper 16005039Paper 15837367Paper 15613305Paper 15582651Paper 15113908Paper 15047819Paper 14963135Paper 11967298
Abstract
The present studies examine the breadth and magnitude of neutralizing antibody (NAb) responses in small animals and rhesus monkeys after various immunization regimens. Using a standardized multi-tier panel of reference Env pseudoviruses for NAb assessment, we show that both protein immunization, and DNA prime, rAd boost immunization, can generate high antibody titers. The potency and breadth of neutralization of primary viruses is still limited. Ongoing optimization of immunogen design will lead to new vaccines to test.
View original record on NIH RePORTER →